{"entity":{"id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","aka":[],"tldr":"A phase 1/2 trial of QL2107 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients is a phase 1/2 interventional study registered as NCT06911827 by Qilu Pharmaceutical Co., Ltd., with 149 participants planned, started 2025-05-09 and due to reach its primary completion in 2027-12. Interventions recorded: QLP2117 and QL2107.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06911827","url":"https://clinicaltrials.gov/study/NCT06911827"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ql2107"],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06911827","phase":"1/2","setting":"A Phase Ib/II Open-Label, Dose-Escalation and Dose-expansion Clinical Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrolled":149,"outcomes":[]},"route":"/trials/nct06911827/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}]}}